David Enloe, Recro Pharma CEO

Re­cro takes on big broth­er role with opi­oid ad­dic­tion drug mak­er, han­dling man­u­fac­tur­ing du­ties and ad­vis­ing on FDA work

Just three weeks ago, CD­MO Re­cro Phar­ma ex­pand­ed its foot­print to the West Coast, as it ac­quired San Diego-based Irisys for $50 mil­lion cash. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.